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Calcium dysregulationBACE1 is a novel type I transmembrane aspartyl protease that has been implicated in the pathogenesis of
Alzheimer's disease. Cleavage of the amyloid precursor protein by the β-secretase, BACE1, is the ﬁrst step in
the production of the Aβ peptide and is a prime target for therapeutic intervention. Using circular dichroism,
we reveal that the secondary structure of BACE1 in a membrane environment is signiﬁcantly different from
what was determined from the previously resolved crystal structure, and, we provide the ﬁrst evidence that
show differences in stability between the active (pH 4.8) and inactive (pH 7.4) forms of BACE1. In this study
we have also examined Ca2+ binding to BACE1, the effect of this binding on the secondary and tertiary
structural characteristics of BACE1, and the inﬂuence of this binding on the speciﬁc activity of the puriﬁed
protein. Circular dichroism and endogenous tryptophan ﬂuorescence measurements demonstrated that the
secondary and tertiary structures, respectively, are sensitive to increasing concentrations of Ca2+. Isothermal
titration calorimetry was then used to characterize the Ca2+–BACE1 interaction in more detail. Our results
suggest that there is a high afﬁnity of binding (kd=2.0×μM) between Ca2+ and BACE1 and that the binding
process was exothermic (ΔH=−3.5 kcal/mol). We also could demonstrate that low concentrations of Ca2+
(μM range) signiﬁcantly increased the proteolytic activity of BACE1. Collectively, these results identify a direct
interaction between BACE1 and Ca2+ and suggest that under physiological conditions, the function(s) of
BACE1 must also be inﬂuenced by Ca2+.© 2009 Elsevier B.V. All rights reserved.1. Introduction
Alzheimer's disease (AD) is a major neurodegenerative disorder of
the aging brain and is characterized by progressive cognitive
deterioration, neuropsychiatric symptoms and behavioural changes.
Although amyloid plaques in AD diseased brains were ﬁrst described
in the early 20th century by Alzheimer, the aetiology of AD remains
uncertain. However, it is well known that the major constituent of
these plaques is a 40–42 amino acid peptide, termed amyloid-β (Aβ),
which originates from a larger precursor protein called the amyloid-β
precursor protein (APP). The processing of APP involves 3 major
classes of enzymes; the α, β, and γ secretases. These enzymes are
differentiated on the basis of the location of their cleavage sites. The α
and β cleavage sites are located close to the membrane while the γ
cleavage site is located within the transmembrane domain. Processing
of APP occurs through two pathways; the α–γ and β–γ secretase
pathways. Sequential cleavage of APP by α- and γ-secretases does notience Foundation Grant 3100-
+41 61 267 21 89.
y).
ll rights reserved.generate the Aβ peptide; whereas sequential β- and γ-secretase
cleavage of APP generates either the Aβ1–40 or Aβ1–42 peptide.
The β-secretase, BACE1, has been implicated in the pathogenesis of
AD. It is a novel type I transmembrane aspartyl protease that cleaves
APP at the SEVKM↑DAEFR sequence and is active in an acidic medium
in a pH range of 4–5 [1,2]. Expression of BACE1 is conﬁned mainly to
neurons and is required for peripheral nerve myelination and axonal
bundling by Schwann cells [2]. Synthesized as a 501-amino acid-long
preproprotein, BACE1 is fully enzymatically active when processed as
a 456 residue membrane-bound protein [3–5]. The active site of
BACE1, two aspartyl acid residues at positions 93 and 289, is located in
the N-terminal or extracellular region (412 residues). The C-terminal
domain of BACE1 harbours a 21 amino acid transmembrane domain
and a 23 residue intracellular region. Recombinant BACE1, devoid of
both the transmembrane and intracellular regions, was found to be
fully active and its crystal structure in complex with high afﬁnity
inhibitors was previously resolved [6,7]. However, the structure of
BACE1 incorporated into a membrane environment may not be
identical to the previously determined crystal structure.
Calcium ions, as well as several others, play important roles in
neuronal processes and it is quite surprising that the role of these ions
on both BACE1 structure and activity have not been investigated
systematically. Angeletti et al. [8] showed that a peptide encompass-
ing the BACE1 cytoplasmic domain is capable of binding Cu(I). They
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modulate APP processing and Aβ release without providing quanti-
tative data concerning the BACE1–Cu(I) interaction and its affect on
BACE1 activity. A link between Ca2+ and BACE1 activity has also been
reported by Bennett et al. [9] demonstrating that BACE1 activity
decreased substantially when intracellular Ca2+ stores were depleted
using a Ca2+ ionophore. But once again, the BACE1–Ca2+ interaction
was not directly investigated.
In the present work we have used spectroscopic and thermo-
dynamic methods to investigate the conformation and stability of
BACE1 in a membrane-like environment. Circular dichroism spectro-
scopy was applied to quantitate the secondary structural elements of
BACE1 in a membrane-like environment and clear differences to the
crystallized ectodomain were observed. Temperature-scans of CD and
UV spectra were performed to compare the stability of active BACE1
(at pH 4.8) and inactive BACE1 (at pH 7.4) and surprisingly the
inactive form was structurally more stable than the active form. As
mentioned above, there has been no biophysical study to date that has
directly investigated the possibility of a speciﬁc interaction between
BACE and Ca2+. Therefore, we have performed Ca2+ binding studies to
elucidate the role of Ca2+ on both BACE1 structure and activity.
Calcium binding to BACE1 was quantitated with isothermal titration
calorimetry. The binding constant, K0, the reaction enthalpy, ΔH°, and
the reaction entropy, ΔS°, could be derived. Our results provide
evidence that Ca2+ binds to full-length BACE1 with a high afﬁnity and
that low concentrations of Ca2+ can modulate the enzymatic activity.
The Ca2+–BACE1 interaction could therefore play an important role in
the generation of the Aβ peptide during disruptions in Ca2+
homeostasis.
2. Materials and methods
2.1. BACE1 expression and puriﬁcation
cDNA encoding the aspartyl protease BACE1 was modiﬁed by PCR
in the 5′ non-coding region to optimize ribosomal recognition and at
the 3′ end by adding sequences encoding 6×His residues to enable
rapid puriﬁcation of the recombinant proteins. Expressionwas carried
out in Sf9 insect cells via recombinant baculovirus. The Sf9 cells,
containing BACE1, was a kind gift.
BACE1 was puriﬁed from isolated membranes of the collected
cells as described by Leitch et al. [10]. The cells were suspended in
cold buffer (PBS, 10 mM imidazole, 1 % Triton X-100, and pH 8.0),
homogenized and stirred on ice for ∼15 min. The homogenate was
centrifuged at 100,000 g for 15 min at 4 °C and ﬁltered. The resulting
supernatant was immediately loaded on an equilibrated Ni2+-
nitrilotriacetic acid-agarose column (25 ml, Qiagen, Germany) and
washed with ﬁve column volumes of 50 mM sodium phosphate (pH
8.0), 10 mM Tris–HCl, 10 mM imidazole, 100 mM sodium chloride
and 0.1% Triton X-100. The column was then washed with ﬁve
column volumes of 50 mM sodium phosphate (pH 7.4), 10 mM
imidazole, 100 mM sodium chloride and 0.1% Triton X-100. BACE1
was eluted using an imidazole gradient and the BACE1 containing
fractions were pooled and then loaded onto a previously equilibrated
HiTrap Q column (5 ml, Amersham Biosciences, Inc.). The column
was then washed with ﬁve column volumes of 50 mM Tris–HCl (pH
7.4), 100 mM sodium chloride and 0.1% Triton X-100. The eluted
BACE1 (ﬂow through fraction) was then loaded onto a HiTrap S
column (5 ml, Amersham Biosciences, Inc.) and a HiTrap Q column
(5 ml, Amersham Biosciences, Inc.) connected in series. Both columns
were washed with ﬁve column volumes of 50 mM Tris–HCl (pH 7.4),
100 mM sodium chloride and 0.1% Triton X-100. The columns were
then eluted separately using a sodium chloride gradient (10 mM–
1 M). The puriﬁed protein was found in the fractions recovered from
the HiTrap Q column. Essentially, homogenous full-length BACE1 was
obtained.2.2. Circular dichroism spectroscopy
Circular dichroism spectra in the far-ultraviolet (190–230 nm)
were recorded using a Chirascan spectrapolarimeter (Applied Photo-
physics, UK). The absorbance at 222 nm of the protein/reagents
mixture was checked to ensure that it did not exceed an optical
density of 1.0. A 1 mm cell was used and spectra were collected
between 200 and 260 nm. Baselines were established using the
appropriate buffers and 20 spectra were collected for each tempera-
ture and averaged.
2.2.1. Thermal unfolding measurements
Aliquots of BACE1 (3 μM) were dissolved and dialyzed against
either 20 mm Hepes (pH 7.4) and 150 mM sodium chloride or 20 mM
Acetate (pH 4.8) and 150 mM sodium chloride. The temperature (5–
95 °C) was controlled by a Series 800 temperature controller (Alpha
omega instruments Corp., USA).
2.2.2. Ca2+ binding experiments
Aliquots of BACE1 (3 μM) were dissolved and dialyzed against
either 20 mm Hepes (pH 7.4) and 150 mM sodium chloride or 20 mM
Acetate (pH 4.8) and 150 mM sodium chloride. The temperature
(25 °C) was controlled by a Series 800 temperature controller (Alpha
omega instruments). BACE1 was incubated with varying amounts of
CaCl2, as indicated, for 30 min at 25 °C prior to the collection of
spectra. Secondary structural features were calculated from the
collected spectra using a computer program following the method
of Yang et al. [11].
2.3. Endogenous tryptophan ﬂuorescence measurements
Tryptophan ﬂuorescence was measured at room temperature in an
F-4500 ﬂuorescence spectroﬂuorimeter (Hitachi Ltd., Japan). The
excitation wavelength was 287 nm and emission spectra were
measured between 300 and 400 nm. Aliquots of BACE1 (10 μg) were
dissolved in either 20 mm Hepes (pH 7.4) and 150 mM sodium
chloride or 20 mM Acetate (pH 4.8) and 150 mM sodium chloride
followed by the addition of Ca2+ to the ﬁnal concentration indicated.
2.4. Isothermal titration calorimetry
BACE1 was diluted in 20 mM Hepes (pH 7.4) and 150 mM NaCl to
reach a concentration of 3 μM prior to the binding measurement.
Isothermal titration calorimetry was performed at a temperature of
25 °C and conducted at reference power of 17 μcal/s under a constant
stirring speed of ∼310 rpm using a MicroCal VP-ITC MicroCal
instrument (MicroCal, Northampton, MA). To avoid air bubbles, all
solutions were degassed under vacuum prior to use. The syringe was
ﬁlled with 20 mM Hepes (pH 7.4), 150 mM NaCl, and 1 mM CaCl2 and
was added to the protein solution in the calorimetry sample cell in 3 μL
steps at 300 s intervals. The binding constant, Kd, the stoichiometry
value, n, and the enthalpy of reaction, ΔH°, were measured directly
from the heat released during the Ca2+–BACE1 interaction. The free
energy and entropy of binding were determined from ΔH° and Kd
values, as ΔG°=−RTlnKd and ΔG°=ΔH°−TΔS°.
2.5. Activity assays
All BACE1 activity assays were performed at 20 °C on a SpectraMax
M2 (Molecular Devices Corporation, Sunnyville, CA)microplate reader
using a 96 well plate. The assay volumewas 100 μL. Typically, 0.5 μg of
BACE1was added to 70 μL of 80mMacetate (pH 4.5), 90mMNaCl, and
0.1% triton (reaction buffer). The reaction was started by adding 30 μL
of the reaction buffer, premixed with 1 μL of the FS-1 substrate
(2.5 mM). In activity assays containing both BACE1 and Ca2+, BACE1
was initially incubated with the desired concentration of Ca2+ for
Fig. 1. Determination of the thermal unfolding proﬁle of the active (pH 4.8, blue solid
squares) and inactive (pH 7.4, red open circles) forms of BACE1. Ellipticity at 222 nmwas
used to determine the percentage folding of the protein as a function of temperature.
Inset: far-UV CD spectra of active BACE1 (pH 4.8) at 5 °C (black) and 95 °C (red). In cases
where error bars appear missing, the deviation in the data is so small that they cannot
be detected.
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reaction was started as described above. The progression of the
ﬂuorescence increase was measured at λemission=520 nm with
ﬂuorescence excitation at λexcitation=430 nm. The activity was
determined from the linear region on the reaction progression curve
(typically up to 800 s). The reaction was followed for 4000 s in 40 s
steps, with gentle agitation in between measurements.
3. Results
3.1. BACE1 conformation
Circular dichroism spectra of BACE1 in a membrane-like environ-
ment at 25 °C were recorded at pH 4.8 (active conformation) and pH
7.4 (inactive conformation) (spectra not shown). Secondary structural
features were calculated from the CD spectra using a computer
program that followed the method of Yang et al. [11]. No signiﬁcant
differences were found in the secondary structure between the activeFig. 2.Measurement of the percentage (%) ofα-helical and β-sheet content of the active
(pH 4.8) and inactive (pH 7.4) forms of BACE1 as a function of Ca2+ concentration. Prior
to the determination of secondary structure, BACE1 was incubated with varying
amounts of Ca2+ for 30 min at 25 °C. Secondary structural content was calculated as
described in Materials and methods. BACE1 α-helical content at pH 4.8 (○) and at pH
7.4 (▪); BACE1 β-sheet content at pH 4.8 (●) and at pH 7.4 (□). In cases where error
bars appear missing, the deviation in the data is so small that they cannot be detected.(α-helix 56%, β-structure 19% and random coil 25%) and inactive (α-
helix 58%, β-structure 17% and random coil 25%) forms of BACE1. We
then compared the structure of our full-length BACE1 in a membrane-
like environment with the previously determined crystal structure of
the soluble ectodomain of the protein. The secondary structural
content derived from the crystal structure of the soluble BACE1
ectodomain (α-helix 15%, β-structure 38% and random coil 47%; 6, 7)
varied signiﬁcantly from our CD data. The CD spectra provides
evidence that BACE1 adopts a signiﬁcantly different conformation
when associated with a membrane environment. Surprisingly, the
crystallized ectodomain (90% of the full-length protein) displays less
structure than the solubilized full-length BACE1. In particular, the α-
helix content of full-length BACE1 is 58% compared to only 15% in the
crystallized ectodomain.
To date, the majority of BACE1 inhibitors designed to interact with
the active site of the protease have been modeled according to the
ectodomain crystal structure. However, as the enzyme structure in
solution is quite different from that of the crystal structure, this
modeling approach may lead to inhibitors of sub-optimal in vivo
efﬁcacy.
3.2. Thermal stability assays
It is known that differences in protein stability, as a result of pH
changes, can modulate the protein's activity. As BACE1 is enzymati-
cally active at pH 4–5 but inactive at physiological pH 7.4 we were
interested if this difference was also reﬂected in the thermodynamic
stability of the protein. Therefore, thermal denaturation experiments
were performed on the active (pH 4.8) and inactive (pH 7.4) forms of
BACE1. Fig. 1 then summarizes the thermal unfolding of BACE1 as
observed with CD spectroscopy.
At a temperature of 5 °C, BACE1 is in its native conformation.
Denaturation of BACE1 was monitored using the ellipticity values at
222 nm. For both forms of BACE1, a temperature-dependent change in
far-UV ellipticity was apparent during the thermal denaturation
experiments (Fig. 1 inset, data shown for active BACE1) and the
ellipticity at 222 nmdecreasedmarkedlywith increasing temperature.
The thermal unfolding pattern of both the active and inactive forms of
BACE1 followed a two-state unfolding proﬁle (Fig. 1). The active form
of BACE1 exhibited a melting temperature (Tm) of 51 °C, thus being
stable at normal physiological temperatures. Again in contrast to our
expectations, the inactive form of BACE1 was even more stable and a
plateau value of denaturation could not be observed. The midpoint ofFig. 3.Measurement of the change in the emitted ﬂuorescence of the active (pH 4.8, ○)
and inactive (pH 7.4, ▪) forms of BACE1 as a function of Ca2+ concentration. In all
ﬂuorescence experiments, aliquots of BACE1 (10 μg) were incubated for 30 min at room
temperature in the presence of various concentrations of Ca2+ followed by spectro-
photometric analysis.
Fig. 4. Quantiﬁcation of Ca2+ binding to BACE1. Isothermal titration calorimetry was
performed to examine the interaction between Ca2+ and BACE1. The solid line
corresponds to the theoretical model assuming a 1:1 binding stoichiometry. The data
presented represents the results from three independent experiments.
Fig. 5. Inﬂuence of Ca2+ on BACE1 activity. Speciﬁc activity of BACE1 at each Ca2+
concentrationwasmeasured and expressed in % relative to the speciﬁc activity of BACE1
in the absence of Ca2+. In activity assays containing both BACE1 and Ca2+, BACE1 was
initially incubated with the desired concentration of Ca2+ for 30 min prior to the
addition of the ﬂuorogenic substrate.
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∼84 °C.
The lower stability of the active form of BACE1 compared to the
inactive form was further corroborated by chemical unfolding
experiments of both forms of BACE1 using urea, a typical chaotropic
agent [12,13]. The urea concentration at the midpoint of the unfolding
transition for active BACE1 was reached at a urea concentration of
2.4 M, whereas inactive BACE1 was stable up to 3.4 M (data not
shown). In agreement with the thermal denaturation study above, the
active form of BACE1 was less stable against urea denaturation than
the inactive form.
3.3. Circular dichroism study of the BACE1–Ca2+ interaction
Almost nothing is known if and towhich extent BACE1may interact
with Ca2+ ions. As a ﬁrst step, circular dichroism spectroscopy was
utilized to investigate Ca2+ binding to BACE1. A signiﬁcant decrease in
the magnitude of ellipticity at 222 nmwas observed in both the active
and inactive forms of BACE1 as the Ca2+ concentration was increased
from 0 to 500 μM (data not shown). Analysis of the CD spectra
(190–240 nm) showed that in both cases, the Ca2+-induced conforma-
tional change were characterized by a decrease in α-helical content by
20% and a corresponding increase in β-sheet structure by 10% (Fig. 2).
However, as seen in Fig. 2, the active form of BACE1 was markedly
more sensitive to the Ca2+-induced changes, especially at Ca2+
concentrations below 100 μM. From the CD spectra, an approximate
dissociation constant, kd, of Ca2+ of 25 μM and 35 μM could be
deduced for the active and inactive forms of BACE1, respectively. The
error associated with the above kd values is rather large since the CD
spectra have a relatively low signal-to-noise ratio. Nevertheless, they
clearly demonstrate that the active form ismore sensitive to Ca2+ than
the inactive form.
3.4. Endogenous tryptophan ﬂuorescence study of the BACE1–Ca2+
interaction
Full length BACE1 has 8 endogenous tryptophan residues. There-
fore, we decided to further explore the effect of Ca2+ on the
conformational state of the active and inactive forms of BACE1 using
endogenous tryptophan ﬂuorescence. Emission spectra were mea-
sured by excitation at 287 nm and the emitted light was monitored
between 300 and 400 nm. Maximum emission of BACE1 was at
332 nm, revealing that the measured tryptophans are located in a
hydrophobic environment. The steady state ﬂuorescence emission
spectrums of the active and inactive forms of BACE1 were then
recorded in the presence and absence of Ca2+. For both enzyme forms,
increasing concentrations of Ca2+ changed the emission spectrum
distinctly. Although the λMAX for BACE1 remained unchanged at
332 nm, suggesting no change in hydrophobicity, there was a
reduction in the ﬂuorescence intensity with increasing concentrations
of Ca2+ (Fig. 3).This quenching of ﬂuorescence is only possible if Ca2+ binding
alters the conformation of BACE1, moving some tryptophans close to
amino acids such as aspartic and glutamic acid, which are known
quenchers of tryptophan ﬂuorescence. Dissociation constants of Ca2+
of 9 μM and 11 μM were derived for the active and inactive forms of
BACE1, respectively. These values are more accurate and clearly
smaller than the approximate dissociation constants determined
by CD.
3.5. Isothermal titration calorimetry of the BACE1–Ca2+ interaction
Both CD spectroscopy and tryptophan ﬂuorescence measurements
provided clear evidence for a BACE1–Ca2+ interaction. In order to
achieve a thermodynamic characterization, isothermal titration calori-
metry was used as the method of choice as it allows a simultaneous
determination of the dissociation constant and the reaction enthalpy.
We performed Ca2+-into-BACE1 (3 μM) titrations and used Ca2+
concentrations of 1 mM in the injection syringe. The integration of the
titration peaks (data not shown) yields the heats of reaction as seen in
Fig. 4. An excel programwas used to carry out the ﬁtting.
In Fig. 4, the solid line corresponds to the theoretical ﬁt for a 1:1
stoichiometry, whereas the red circles represent the experimental
data. At 25 °C, the binding process is exothermic with a reaction
enthalpy of ΔH°=−3.5 kcal/mol and a dissociation constant of Kd=
2.0 μM. The latter value is in broad agreement with the dissociation
constant determined by endogenous tryptophan ﬂuorescence. The
free energy of binding follows from the binding constant according to
the equation ΔG°=RT ln Kd (RT is the kinetic energy) and is ΔG°=
−3.36 kcal/mol at 25 °C. The corresponding entropic contribution to
the binding of Ca2+ to BACE1 follows from the Gibbs–Helmoltz
equation, ΔG°=ΔH°−TΔS°, leading to TΔS°=0.14 kcal/mol K and a
ΔS°=0.47 kcal/mol. It can be concluded that Ca2+ binding to BACE1 is
almost exclusively enthalpy-driven at 25 °C.
3.6. BACE1 activity assay
It is clear from the previous spectroscopic and thermodynamic
data that a direct interaction occurs between BACE1 and Ca2+. We
have therefore investigated the role of Ca2+ on the functional activity
of BACE1. Activation assays were performed in the absence and
presence of various concentrations of Ca2+. In these experiments, a
ﬁxed amount of BACE1 (0.5 μg) was incubated with varying amounts
of Ca2+ for 30 min prior to the addition of the ﬂuorogenic APP
substrate. In the presence of up to 7 μM Ca2+, an increase in BACE1
1937M. Hayley et al. / Biochimica et Biophysica Acta 1788 (2009) 1933–1938activity was observed compared to BACE1 in the absence of Ca2+. A
Ca2+ concentration of 1 μM gave the highest recorded BACE1 activity
(Fig. 5).
Interestingly, at higher concentrations of Ca2+,10 and 50 μM,when
compared to BACE1 in the absence of Ca2+, there was a decrease in
protein activity (Fig. 5).
4. Discussion
To date, there has been no study that has directly examined an
interaction between BACE1 and Ca2+. Using various techniques (CD,
endogenous tryptophan ﬂuorescence and ITC) we provide the ﬁrst
evidence for a direct interaction between BACE1 and Ca2+. Circular
dichroism and endogenous tryptophan ﬂuorescence both revealed
Ca2+-dependent structural changes in the protein (Fig. 2 and Fig. 3,
respectively). More speciﬁcally, isothermal titration calorimetry
revealed that BACE1 binds Ca2+ with a high afﬁnity (Kd=2.0 μM,
Fig. 4) and that the BACE1–Ca2+ interaction is primarily enthalpy-
driven (ΔH°=−3.5 kcal/mol), whereas the entropy change is close to
zero. In addition, we have investigated if the BACE1–Ca2+ interaction
had any effect on BACE1 activity. We show that at low concentrations
of Ca2+, the BACE1–Ca2+ interaction signiﬁcantly increases the
proteolytic activity of the protein (Fig. 5).
To the best of our knowledge, this has been the ﬁrst biophysical
study conducted on BACE1. We reveal that the secondary structure of
full-length BACE1 in a membrane-like environment is signiﬁcantly
different from what is calculated from the previously resolved crystal
structure. The full-length form of the protein is signiﬁcantly more
structured than the soluble ectodomain (90% of the full-length
protein) as a result of an increase in α-helix by 43%. It is essential to
recognize that BACE1 is an integral membrane protein and that its
structure is inﬂuenced by its membrane environment. The signiﬁcant
difference in structure between full-length BACE1 and the soluble
ectodomainmust surely have consequences with regards to the in vivo
efﬁcacy of BACE1 inhibitors. In addition, our CD data provides the ﬁrst
evidence showing differences in stability between active (pH 4.8) and
inactive (pH 7.4) BACE1. Active BACE1 (Tm∼51 °C) is comparably
much less stable than the inactive form (Tm∼84 °C) (Fig. 1). This
difference in stability may be a regulation mechanism to restrict
unwanted and unnecessary activity for the inactive form of BACE1,
especially at the cell surface.
It is well established that both the Aβ peptide and the tau protein
are neurotoxic factors that are involved in the pathogenesis of AD.
However, there is a large body of evidence that suggests that
alterations to Ca2+ homeostasis may initiate the above processes.
The Ca2+ dysregulation hypothesis, which was initially proposed
20 years ago, suggests that an altered Ca2+ regulation might play a
role in both brain aging and AD [14–20]. The BACE1–Ca2+ interaction
is very important with regards to abnormalities in neuronal Ca2+
homeostasis. Disruptions that result in a signiﬁcant increase in the
cytoplasmic Ca2+ concentration has been shown to induce a high
production of intraneuronal Aβ peptide [21], and is in agreement
with our ﬁndings that Ca2+ increases the proteolytic activity of
BACE1. The results presented here allow us to deﬁne a working
model for the BACE1–Ca2+ interaction and its importance in the
production of Aβ. In this model, cell surface-associated integral
membrane proteins BACE1 and APP are internalized to endosomes,
the main site for APP cleavage by BACE1 and the production of the
Aβ peptide. The outer leaﬂet of the endosomal membrane contains a
high percentage of negatively charged lipids (15.7%, [22]). Calcium
ions are attracted to these areas and electrostatic considerations
based on Boltzmann's law and the Gouy-Chapman theory predicts an
at least a 10-fold large Ca2+ surface concentration composed to bulk
solution. This may be enhanced even more when there is an increase
in the concentration of cystosolic Ca2+ due to disruptions in Ca2+
homeostasis. The original intracellular domain of BACE1 afterendosome formation remains on the endosome outer leaﬂet and
remains in contact with the cytoplasm. This intracellular domain
contains a putative metal-binding motif Cys-Xaa-Xaa-Cys, one
additional cysteine, as well as other potential Ca2+-binding residues.
Cytosolic Ca2+, as a result of disruptions in Ca2+ homeostasis
(cytosolic [Ca2+]∼1–3 μM during Ca2+ dysregulation, [21,23]) would
be able to bind to the intracellular domain of BACE1 through one or
more of these binding sites, enhancing its proteolytic activity,
thereby increasing Aβ production. An increased production of the
Aβ peptide would lead to further alterations in Ca2+ homeostasis,
creating a positive feed back loop, as reviewed in Bojarski et al. [24].
Since the disruption of Ca2+ homeostasis plays an important role in
both aging and AD pathogenesis, our study suggests that pharma-
logical treatment aimed at both attenuating elevated Ca2+ signalling
and blocking the Ca2+ binding site(s) in BACE1, could be beneﬁcial
for AD patients.Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at doi:10.1016/j.bbamem.2009.05.015.References
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